Display options
Cite
Turan T, Izgi HB, Ozsoy S, et al. The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. Psychiatry Investig. 2009;6(3):204-10doi: 10.4306/pi.2009.6.3.204.
Turan, T., Izgi, H. B., Ozsoy, S., Tanrıverdi, F., Basturk, M., Asdemir, A., Beşirli, A., Esel, E., & Sofuoglu, S. (2009). The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. Psychiatry investigation, 6(3), 204-10. https://doi.org/10.4306/pi.2009.6.3.204
Turan, Tayfun, et al. "The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome." Psychiatry investigation vol. 6,3 (2009): 204-10. doi: https://doi.org/10.4306/pi.2009.6.3.204
Turan T, Izgi HB, Ozsoy S, Tanrıverdi F, Basturk M, Asdemir A, Beşirli A, Esel E, Sofuoglu S. The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. Psychiatry Investig. 2009 Sep;6(3):204-10. doi: 10.4306/pi.2009.6.3.204. Epub 2009 Jun 23. PMID: 20046396; PMCID: PMC2796068.
Copy Download .nbib Format: NLM
Share it on

Psychiatry Investig. 2009 Sep;6(3):204-10. doi: 10.4306/pi.2009.6.3.204. Epub 2009 Jun 23.

The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.

Psychiatry investigation

Tayfun Turan, Hasan Basri Izgi, Saliha Ozsoy, Fatih Tanrıverdi, Mustafa Basturk, Akif Asdemir, Aslı Beşirli, Ertugrul Esel, Seher Sofuoglu

Affiliations

  1. Department of Psychiatry, Erciyes University Medical School, Kayseri, Turkey.

PMID: 20046396 PMCID: PMC2796068 DOI: 10.4306/pi.2009.6.3.204

Abstract

OBJECTIVE: Mental fatigue, cognitive disorders, and sleep disturbances seen in chronic fatigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypoactivity seen in CFS. Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4-week administration of galantamine hydrobromide, a selective acetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment.

METHODS: Basal levels of cortisol and DHEAS were measured in 29 untreated CFS patients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 20 healthy controls. In the patient group, four weeks after 8 mg/d galantamine hydrobromide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 patients who stayed in study were divided into two subgroups as responders and nonresponders according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) scores.

RESULTS: Important findings of this study are lower pre-and post-treatment cortisol levels and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, respectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which were normalized following four weeks' treatment with 8 mg/d galantamine hydrobromide in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively).

CONCLUSION: The findings of the decrease in basal DHEAS levels and DHEAS/cortisol molar ratios normalizing with galantamine treatment may give some support to the cholinergic deficit hypothesis in CFS.

Keywords: Chronic fatigue syndrome; Cortisol; Dehydroepiandrosterone sulfate; Galantamine hydrobromide

References

  1. Psychoneuroendocrinology. 2004 Jul;29(6):724-32 - PubMed
  2. J Affect Disord. 1999 Jul;54(1-2):129-37 - PubMed
  3. J Clin Endocrinol Metab. 1971 Jul;33(1):87-92 - PubMed
  4. Lancet. 1999 Feb 6;353(9151):455-8 - PubMed
  5. J Clin Endocrinol Metab. 1991 Dec;73(6):1224-34 - PubMed
  6. Biol Psychiatry. 1997 Feb 1;41(3):311-8 - PubMed
  7. J Clin Endocrinol Metab. 1995 Nov;80(11):3390-1 - PubMed
  8. Anaesthesia. 1974 Mar;29(2):163-8 - PubMed
  9. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 - PubMed
  10. Psychiatry Investig. 2008 Dec;5(4):209-12 - PubMed
  11. Neuropsychobiology. 2001 Jan;43(1):34-41 - PubMed
  12. Int J Mol Med. 1998 Jan;1(1):143-6 - PubMed
  13. Brain Res Bull. 2001 May 15;55(2):319-25 - PubMed
  14. Horm Metab Res. 1999 Jan;31(1):18-21 - PubMed
  15. Br J Psychiatry. 2001 Sep;179:243-9 - PubMed
  16. J Clin Endocrinol Metab. 1985 May;60(5):947-52 - PubMed
  17. Acta Anaesthesiol Scand. 1980 Jun;24(3):166-8 - PubMed
  18. Psychoneuroendocrinology. 1982;7(4):347-54 - PubMed
  19. Psychosom Med. 2002 Nov-Dec;64(6):951-62 - PubMed
  20. J Affect Disord. 1998 Jan;47(1-3):49-54 - PubMed
  21. J Clin Pharmacol. 1999 Apr;39(4):327-48 - PubMed
  22. Clin Endocrinol (Oxf). 2000 Jul;53(1):99-106 - PubMed
  23. Am J Psychiatry. 2001 Apr;158(4):641-3 - PubMed
  24. Endocr Res. 1991;17(1-2):237-65 - PubMed
  25. J Physiol. 1993 Aug;468:515-27 - PubMed
  26. Psychol Med. 1996 Mar;26(2):245-56 - PubMed
  27. Psychoneuroendocrinology. 1998 Feb;23(2):103-13 - PubMed
  28. J Affect Disord. 1998 Jan;47(1-3):191-4 - PubMed
  29. J Clin Endocrinol Metab. 1992 Oct;75(4):1002-4 - PubMed
  30. Am J Psychiatry. 2002 Jul;159(7):1237-9 - PubMed
  31. Ann Intern Med. 1994 Dec 15;121(12):953-9 - PubMed
  32. Psychiatry Res. 2000 Dec 4;97(1):21-8 - PubMed
  33. J Clin Endocrinol Metab. 2001 Aug;86(8):3545-54 - PubMed
  34. Biol Psychiatry. 1998 Feb 15;43(4):293-302 - PubMed
  35. Br J Psychiatry. 1995 Oct;167(4):503-6 - PubMed
  36. Brain Res. 1987 Mar 17;406(1-2):357-62 - PubMed
  37. Aging Clin Exp Res. 2006 Apr;18(2):167-70 - PubMed
  38. JAMA. 2004 Sep 8;292(10):1195-204 - PubMed
  39. Psychol Med. 2001 Nov;31(8):1331-45 - PubMed
  40. Br J Psychiatry. 1982 Nov;141:518-23 - PubMed

Publication Types